Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.4K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.4K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.0K
Structure and Function of Platelets01:18

Structure and Function of Platelets

4.0K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Introduction to Hemostasis01:05

Introduction to Hemostasis

15.2K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
15.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of socioeconomic deprivation on inequities in care outcomes of haematological malignancies treated with stem cell transplant in the UK: a systematic review protocol.

BMJ open·2026
Same author

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same author

Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors.

The Cochrane database of systematic reviews·2026
Same author

Convalescent plasma for people with COVID-19.

The Cochrane database of systematic reviews·2026
Same author

Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).

Critical care medicine·2026
Same author

Intermediate dose heparin thromboprophylaxis among critically ill patients with COVID-19: a randomized clinical trial.

Journal of thrombosis and haemostasis : JTH·2026

Related Experiment Video

Updated: Feb 25, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.6K

Pathogen-reduced platelets for the prevention of bleeding.

Lise J Estcourt1, Reem Malouf, Sally Hopewell

  • 1Haematology/Transfusion Medicine, NHS Blood and Transplant, Level 2, John Radcliffe Hospital, Headington, Oxford, UK, OX3 9BQ.

The Cochrane Database of Systematic Reviews
|July 31, 2017
PubMed
Summary

Pathogen-reduced platelets may increase platelet refractoriness and transfusion needs in thrombocytopenic patients. However, evidence suggests they do not significantly impact bleeding risk or mortality, though more research is needed for non-hematologic/oncologic diagnoses.

More Related Videos

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
10:32

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

14.1K
Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.6K

Related Experiment Videos

Last Updated: Feb 25, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.6K
Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
10:32

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

14.1K
Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.6K

Area of Science:

  • Hematology and Transfusion Medicine
  • Infectious Disease Prevention
  • Clinical Effectiveness Research

Background:

  • Platelet transfusions are crucial for managing bleeding in thrombocytopenic individuals.
  • Despite safety measures, risks of transfusion-transmitted infections persist.
  • Photochemical pathogen reduction aims to mitigate these risks but raises effectiveness concerns.

Purpose of the Study:

  • To evaluate the efficacy of pathogen-reduced platelets in preventing bleeding among patients requiring transfusions.
  • To compare pathogen-reduced platelets against standard platelets in clinical outcomes.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs).
  • Included 12 completed RCTs (2075 participants) comparing pathogen-reduced (Intercept® or Mirasol®) with standard platelets.
  • Searched multiple databases up to October 2016 for relevant studies.

Main Results:

  • High-quality evidence indicates pathogen-reduced platelets increase platelet refractoriness and transfusion requirements.
  • Moderate-quality evidence shows no significant difference in clinically significant bleeding, severe bleeding, or all-cause mortality.
  • No bacterial transfusion-transmitted infections were reported in trials assessing this outcome.

Conclusions:

  • For patients with hematologic or oncologic disorders, pathogen-reduced platelets increase refractoriness and transfusion needs.
  • Moderate-quality evidence suggests no significant impact on mortality or bleeding complications in this population.
  • Insufficient evidence exists for patients with other diagnoses; ongoing trials may provide further insights.